Shun NagaiThis article aims to provide practical, science-based insights into the functional ingredient mannan oligosaccharides (MOS) for pet food product developers, researchers, and marketing professionals.
In recent years, the global pet food market has increasingly emphasized concepts such as gut health and immune support. As a result, there is a growing demand for added value backed by solid scientific evidence. Within this context, MOS has once again attracted attention as a key functional ingredient capable of comprehensively supporting digestive health and immune function in pets.
Importance of MOS as a Functional Ingredient
MOS (Mannan Oligosaccharides) are a type of prebiotic derived from the cell wall of yeast (Saccharomyces cerevisiae). Because MOS is not digested by the pet’s own digestive enzymes, it reaches the large intestine intact, where it directly interacts with the intestinal microbiota and contributes to maintaining gut health.
MOS has a long history of use, having been incorporated into livestock feed and pet food since the 1990s. In particular, the global trend toward restricting the use of antibiotic growth promoters (AGPs) has accelerated interest in MOS as a natural alternative that supports intestinal health and productivity without relying on antibiotics.
This article explores the multifaceted biological mechanisms of MOS and explains how these properties can be translated into practical applications in real-world pet food product development.
Key Functional Properties and Mechanisms of Action of MOS
Unlike conventional prebiotics that primarily serve as substrates for beneficial bacteria, MOS contributes to gut and immune health through a more multifaceted and direct approach. While its mechanisms are interrelated, they can be broadly categorized into three main functions, each of which is discussed below.
Inhibition of Pathogenic Bacteria: The Anti-Adhesion Mechanism
One of the most distinctive functions of MOS is its ability to inhibit the adhesion of mannose-binding pathogenic bacteria. Whereas many prebiotics suppress pathogens indirectly by improving the gut microbiota, MOS can act as a decoy receptor, binding pathogens directly and preventing their attachment to the intestinal epithelium.
The mannose residues that make up MOS are readily recognized by mannose-binding factors (such as FimH) located at the tips of type 1 fimbriae on pathogens such as Escherichia coli and Salmonella. As a result, these bacteria bind preferentially to MOS rather than to intestinal epithelial cells, reducing their ability to colonize the gut.
Pathogens that cannot adhere effectively are less able to proliferate in the intestine and are more easily excreted in the feces. This mechanism may contribute to a reduced pathogen load and a lower risk of intestinal infections.
For example, in a clinical report involving dogs with diarrhea, the pathogen clearance rate for pathogenic E. coli was 85.7% in the MOS-supplemented group, compared with 25% in the non-supplemented group.
Promotion of Beneficial Bacteria and Suppression of Harmful Bacteria
MOS also exhibits prebiotic effects by serving as a substrate for beneficial intestinal bacteria, particularly Lactobacillus and Bifidobacterium. In studies involving healthy adult cats, dietary supplementation with MOS resulted in significant reductions in harmful bacteria such as Clostridium perfringens and E. coli, alongside significant increases in Bifidobacterium and lactic acid bacteria.
A gut environment dominated by beneficial bacteria can lead to several secondary health benefits, including:
Production of Short-Chain Fatty Acids (SCFAs)
Although MOS itself is not a highly fermentable oligosaccharide, improvements in the intestinal environment can promote the establishment of beneficial bacteria, which in turn may positively influence the production of short-chain fatty acids such as butyrate.
When combined with fermentable fibers such as fructooligosaccharides (FOS) or inulin, MOS may help maintain a mildly acidic intestinal pH, creating conditions that inhibit pathogen growth.
Improved Digestive and Absorptive Efficiency
A balanced gut microbiota supports intestinal barrier function and overall gastrointestinal stability. In conditions associated with diarrhea or inflammation, this may contribute to improved digestion and nutrient absorption.
Reduction of Fecal Odor
By shifting the intestinal microbiota toward a beneficial profile and suppressing putrefactive bacteria, MOS may reduce the production of odor-related metabolites such as ammonia, indoles, and phenols, which are typically associated with protein putrefaction. This effect is particularly pronounced when MOS is used in combination with fermentable fibers such as FOS or inulin.
Enhancement of Intestinal Immunity and Systemic Effects
The intestine is often described as the body’s largest immune organ, housing approximately 70% of the immune system. MOS plays an important role in supporting intestinal immunity and strengthening the pet’s natural defense mechanisms.
Enhancement of Mucosal Immunity
Secretory immunoglobulin A (IgA) plays a critical role in preventing pathogen invasion at the intestinal mucosal barrier. MOS may influence intestinal immune responses through improvements in gut health. In canine studies, co-administration of MOS and FOS has been shown to significantly increase IgA secretion in the small intestine.
Modulation of Immune Cell Activity
MOS may also influence immune cell function indirectly via improvements in the intestinal environment. In studies involving dogs, MOS supplementation has been associated with changes in peripheral blood lymphocyte ratios, suggesting a potential impact on immune status.
In vitro studies have further reported changes in macrophage phagocytic activity and modulation of inflammatory cytokine production, indicating that MOS may contribute to immune balance.
Efficacy of MOS in Dogs and Cats
This section reviews scientific evidence demonstrating how the multifunctional properties of MOS translate into measurable effects in dogs and cats. These data can be used as reference points for product development and for substantiating functional claims.
Evidence of Efficacy in Dogs
Multiple studies have demonstrated the effectiveness of MOS in dogs.
Healthy Adult Dogs
Results:
In healthy adult dogs, MOS supplementation has been reported to increase fecal lactic acid bacteria. Some studies have also shown significant increases in small intestinal IgA levels and changes in peripheral lymphocyte ratios when MOS is administered in combination with FOS, suggesting effects on both intestinal and systemic immune indicators.
Conclusion:
These findings suggest that MOS may positively influence gut microbiota balance and immune-related parameters under specific conditions.
Puppies with Gastroenteritis
Results:
In puppies suffering from diarrhea-associated gastroenteritis, clinical reports indicate that the clearance rate of pathogenic E. coli was 85.7% in the group receiving MOS alongside standard treatment, compared with 25% in the non-MOS group.
Conclusion:
These results suggest that MOS supplementation may help reduce intestinal pathogen load when used as an adjunct to conventional therapy, consistent with its anti-adhesion mechanism.
Long-Term Supplementation in Puppies
Results:
In a 150-day long-term study, MOS supplementation did not significantly affect palatability or nutrient digestibility. However, significant changes were observed in immune-related indicators such as the CD4+/CD8+ ratio, as well as significant reductions in serum total cholesterol and LDL cholesterol.
Notably, no significant differences were observed in fecal ammonia or SCFA concentrations.
Conclusion:
This study suggests that long-term MOS supplementation is well tolerated and may influence immune-related markers, while its effects are not primarily dependent on strong fermentation activity.
Evidence of Efficacy in Cats
Although fewer studies are available for cats than for dogs, promising data have been reported. In a six-week feeding trial involving healthy adult cats, the following outcomes were observed:
- Changes in Intestinal Microbiota
Significant reductions in fecal Clostridium perfringens and E. coli, alongside significant increases in Bifidobacterium and Lactobacillus species.
- Changes in Fermentation Products
Increases in short-chain fatty acids such as butyrate and acetate, accompanied by a reduction in fecal pH, suggesting a shift toward carbohydrate-derived fermentation.
- Conclusion:
These findings indicate that MOS derived from yeast cell walls can influence the intestinal microbiota and fermentation environment in cats, contributing to improved gut health.
Formulation Design and Manufacturing Considerations
To translate scientific knowledge into commercial products, it is essential to understand practical considerations related to formulation and manufacturing.
Form and Recommended Inclusion Levels
MOS is typically incorporated into pet food as a yeast cell wall–derived ingredient (e.g., yeast cell wall or yeast cell wall extract). In some formulations, dried yeast ingredients may be used, contributing MOS as well as palatability and nutritional value, although MOS content varies depending on the fraction.
Inclusion levels commonly range from approximately 0.1–0.5%, depending on the product objective and ingredient specification. In practice, formulations often start at 0.1–0.3%, with around 0.1% for maintenance diets and 0.2–0.3% for products with more pronounced functional positioning.
Long-term studies suggest relatively high tolerance, with minimal effects on palatability or digestibility even at higher inclusion levels. Nevertheless, optimal dosing should be determined based on formulation design, ingredient specifications, and target outcomes.
Synergistic Effects with Other Functional Ingredients
In premium pet foods, MOS is commonly used in combination with other prebiotics such as FOS, inulin, or galactooligosaccharides (GOS). This approach reflects a synbiotic design strategy, aiming to leverage complementary mechanisms for broader and more robust effects.
For example, some products combine MOS with chicory-derived inulin to create a stable, gentle intestinal environment that supports beneficial bacteria while minimizing digestive disturbances in sensitive pets.
Stability and Additional Benefits in Manufacturing
MOS offers several technical advantages for pet food developers:
- High Stability:
MOS is relatively resistant to heat and acidity, allowing it to retain functionality through high-temperature, high-pressure processes such as extrusion.
- Contribution to Palatability:
When supplied via yeast-derived ingredients, MOS may also enhance palatability due to the presence of amino acids and nucleotides associated with umami taste.
Comparative Analysis with Other Prebiotics
To support product differentiation, it is important to understand how MOS compares with other commonly used prebiotics such as FOS and inulin.
| Comparison Item | MOS | FOS / Inulin |
|---|---|---|
| Primary mechanism | Direct pathogen binding and exclusion | Indirect suppression via beneficial bacteria |
| Fermentability | Mild (low gas and acid production) | Rapid (higher gas and acid production) |
| Energy contribution | Minimal | Low (~2 kcal/g) |
| Physical properties | Powder, easy handling | Hygroscopic |
Mechanistic Differences
FOS and inulin function primarily as substrates for beneficial bacteria, indirectly suppressing pathogens through microbiota modulation. In contrast, MOS exerts a more direct effect by binding pathogens and preventing epithelial adhesion.
Differences in Fermentation
FOS and inulin ferment rapidly, producing significant amounts of SCFAs and gas. While this can enhance gut health, excessive intake may lead to soft stools or bloating. MOS fermentation is much milder; in canine fecal culture studies, the pH decrease with MOS was only 0.4 compared with 2.0 for FOS.
However, because MOS alone does not strongly promote carbohydrate fermentation, excessive reliance on MOS without complementary fibers may favor protein fermentation and ammonia production. Balanced formulation is therefore important.
Strategic Value and Future Outlook of MOS
As outlined in this article, MOS provides three major, scientifically supported benefits:
- Control of pathogenic bacteria through its unique anti-adhesion mechanism
- Improvement of gut microbiota balance by promoting beneficial bacteria
- Support of immune function, both intestinal and systemic
These properties align closely with current consumer trends emphasizing gut health and immune care. When combined with conventional prebiotics such as FOS, MOS enables comprehensive gut health solutions that span from beneficial bacteria promotion to pathogen exclusion.
Backed by robust scientific evidence, MOS is a reliable functional ingredient that can contribute meaningfully to extending pet healthspan and improving quality of life (QOL). As personalized nutrition continues to evolve, multifunctional ingredients like MOS will serve as foundational components in the development of targeted pet food solutions.